141 related articles for article (PubMed ID: 25096727)
1. Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers.
Firpo MA; Boucher KM; Mulvihill SJ
Theor Biol Med Model; 2014 Aug; 11():34. PubMed ID: 25096727
[TBL] [Abstract][Full Text] [Related]
2. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
3. Serum biomarker panels for the detection of pancreatic cancer.
Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
[TBL] [Abstract][Full Text] [Related]
4. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
5. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y; Holmes MV; Chen Z; Kartsonaki C
J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
7. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
8. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
10. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
11. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
12. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
Jang SI; Lee HK; Chang EJ; Kim S; Kim SY; Hong IY; Kim JK; Lee HS; Yang J; Cho JH; Lee DK
Cancer Immunol Immunother; 2023 Aug; 72(8):2757-2768. PubMed ID: 37165046
[TBL] [Abstract][Full Text] [Related]
13. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
14. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
15. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
16. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
17. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
[TBL] [Abstract][Full Text] [Related]
18. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
